By  – InvestingNews.com March 26th, 2018

Agritek Holdings (OTCMKTS:AGTK)

Agritek is a real estate investor dedicated to the cannabis sector, they also act as consultants for a variety of cannabis brands like California Premiums, Hemp Pops and MicroDose Strips, all offering different types of products.

As part of a letter to shareholders, CEO Michael Friedman said this year the company plans to keep up their momentum from their most recent acquisitions. Moving forward the company is working on the expansion of their developing facilities. “The current year is expected to be a busy year of development and expansion of our multi-pronged real estate and branding company catering to the marijuana industry,” Friedman wrote in his letter.

ABcann Global (OTC:ABCCF)

ABcann is a production company with a licensed facility in Ontario. In January the company completed a $70 million financing deal with Canaccord Genuity and Eight Capital. ABcann also received an import license from the Federal Office of Drug Control in Australia, allowing the company to supply medicinal cannabis to the Australian market.

“This import license is a key milestone towards generating revenue through ABcann’s network of physicians, pharmacists and patients, and advancing the use of medical cannabis,” Barry Fishman, CEO of ABcann said in a statement.

American Cannabis Company (OTC:AMMJ)

This company brings their expertise to other players in the cannabis space offering business planning and market assessment services. The company also sells ancillary products focused on this specific market. So far this year, the company has signed two new contracts with cannabis clients focused on the state of California.

AmeriCann (OTCQX:ACAN)

AmeriCann is an agricultural technology company working on the consultation, design, construction, and financing of facilities for approved and licensed marijuana operators throughout the United States. The company is currently engaged in three facility projects, in three separate states, Denver, Massachusetts, and Illinois. As part of their year-end update filing, the company explained the entire cannabis industry faces four direct obstacles including a scarcity of experts as more markets open up to the growing market.

“Many cannabis entrepreneurs do not have access to the capital required to build the infrastructure required to meet growing demand and sales projections. Traditional sources of financing, such as banks, are not available currently to cannabis producers and retailers,” AmeriCann said.

Arena Pharmaceuticals (NASDAQ:ARNA)

Arena is a traditional biopharmaceutical company working on their pipeline of drug products. However, their APD371 candidate is an orally available product harnessing the cannabinoid-2 receptor seeking to treat visceral pain, directly associated with Crohn’s disease.

As part of their third-quarter results from 2017, the company updated shareholders on the progress of APD371. This program is currently in the phase two stage of development, the company is expecting data from this program in the first quarter of 2018.

Aphria (OTC:APHQF)

Aphria is a Canadian licensed producer (LP) with a current growing capacity of 9,000 kilograms of cannabis product per year, according to their most recent quarterly report, that number is expected to go up with the company’s planned expansions. This year Aphria made the decision to let go of its US assets, including a stake in a company based in Arizona. Aphria is engaged in the process of dropping their stake in Liberty Health Sciences, its US partner.

“While I continue to believe there is tremendous opportunity in the U.S. for medical cannabis, the sale of these shares serve the best interests of our shareholders and provide additional and important capital to fund Aphria’s continued growth in Canada and expand into other federally legal international markets,” Vic Neufeld, CEO of the company said as part of the announcement for their sale of shares in Liberty Health.

Aurora Cannabis (OTC:ACBFF)

Aurora is another Canadian LP working on their strategy in that country. Their proposed Aurora Sky facility, which will produce 100,000 kilograms of cannabis per year, received a cultivation license certification from Health Canada, the government’s regulator, in January.

“The additional cultivation capacity will allow us to further expand our domestic and international market share very quickly, and is expected to significantly accelerate revenue growth this year,” Terry Booth, CEO of the company said in their announcement.

Beleave (OTC:BLEVF)

Beleave’s subsidiary earned a cultivation license from Health Canada in June 2017. This year the company received an additional license from Health Canada to start the commercial production of cannabis oils.

“The company has put a lot of time and effort into researching various extraction techniques and is looking forward to putting this knowledge to good use,” Beleave CEO Andrew Wnek said.

Choom Holdings (OTCQB:CHOOF)

Choom is a Canadian cannabis company with a focus on the retail side of the industry. The company plans to present consumers with the option of products that appeal to the lifestyle aspect of consuming marijuana. The company has been expanding its production with recent acquisitions.

In January the company revealed the concept design for its proposed retail dispensary strategy. “As the Canadian market approaches a new cannabis recreation marketplace, meeting consumer perception and choice with social credibility will be key,” Chris Bogart, president and CEO of Choom said.

Canada House Wellness Group (OTC:SARSF)

This company is working as an operator of other cannabis operations, their goal is to develop strategic partnerships, mergers, and acquisitions. The company earned some market recognition by being added to the list of ventures available to shareholderson the Emerging Marijuana Growers Fund.

“For the benefit of all our shareholders, we’re very pleased to have been included within this ETF, for it should bring more professional investor attention to the fine work our team has been doing to enhance the operations of our three divisions,” Larry Bortles, CEO, and chairman of the company said. “As each of our verticals achieve profitability this year, we look forward to becoming a major contributor to the growth of this ETF.”

CannaRoyalty (OTC:CNNRF)

CannaRoyalty is focused on the operation and management of several cannabis businesses in the US. Their strategy is to create a portfolio of cannabis assets in states where it is legal to sell the product. The company regularly updates shareholders on new deals and tracking its engagement with cannabis ventures in legal states.

After a staff notice from the Canadian Securities Administrators was sent, requiring for cannabis companies operating in the US but publicly traded in Canada, to add an extra disclosure of risks to investors, Marc Lusting CEO of CannaRoyalty commended the move by the regulators.

“The Notice clarifies the regulatory landscape for investors and is favorable for issuers with US cannabis assets,” he said.

CannTrust Holdings (OTC:CNTTF)

CannTrust operates a 50,000 square hydroponic facility in Ontario, under the approval of its LP status. The company is working on a phase 2 expansion to its facility, expected to be completed in mid-2018. CannTrust obtained sales license from Health Canada for its facility in February.

“The expansion of our Greenhouse Facility together with our Health Canada Sales Licence will allow CannTrust to meet growing market demand and provide maximum value to our customers, partners and shareholders,” Eric Paul, CEO of the company said in a statement.

Canopy Growth (OTC:TWMJF)

Canopy is one of the biggest Canadian LPs. The Canadian behemoth earned praise from the industry by brokering a new type of deal last year when alcohol producer Constellation Brands (NYSE:STZ) invested $245 million for 9.9 percent equity of Canopy.

According to their most recent quarterly update, the company announced its recorded revenue had increased to 21.7 million, representing a 123 percent year-over-year revenue growth.

Cronos Group (NASDAQ:CRON)

Cronos is a company that has been targeting a global reach for its products. Their presence recently increased thanks to a new venture in Australia. Cronos Australia officially launched in February 2018. According to the company, this option could expand to reach in markets in New Zealand and Southeast Asia.

“I think what we’ve seen in the market is an increased rate of voices and momentum around medicinal cannabis access for patients beyond those two patient groups,” Rodney Cocks, CEO, and director of the new Australian venture said during an investor call from Cronos.

The company officially joined the Nasdaq this year, launching a movement of other cannabis companies evaluating the possibility to list in this exchange.

Emerald Health Therapeutics (OTC:EMHTF)

Emerald Health oversees a variety of arms for the company with different areas of focus, its subsidiary with an LP status, currently operates out of an indoor facility in B.C., however, the company is working on a 500,000 square feet greenhouse facility in Vancouver.

In January the company announced a partnership with DMG Blockchain Solutions to investigate the use of blockchain supply management systems for the cannabis industry, through an entirely new company, CannaChain Technologies.

“There are notable new applications of blockchain technology to validate and assure the source, quality, and integrity of products such as diamonds, wine, and art, along with coffee and other food products,” Avtar Dhillon executive chairman of Emerald Health Therapeutics said in their statement.

GW Pharmaceuticals (NASDAQ:GWPH)

GW is another traditional pharma company trading on the NASDAQ exchange. One of their main areas of focus is the treatment epilepsy conditions with their lead cannabinoid product candidate, Epidiolex. GW is currently evaluating this candidate against Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis and infantile spasms.

In December of 2017, the company announced it had been accepted for its New Drug Application (NDA) application for Epidiolex with the U.S. Food and Drug Administration (FDA).

iAnthus Capital Holdings (OTCQB:ITHUF)

iAnthus is another operator looking for companies in the US market. Their most recent area of focus is Florida, thanks to a substantial acquisition in the state. The company bought the assets of GrowHealthy Holdings.

“The GrowHealthy cultivation and operations team has already established itself as a leader in Florida’s medical cannabis market, and we look forward to contributing iAnthus’ capital and operational resources to fully build out GrowHealthy’s infrastructure,” Randy Maslow, president of iAnthus said in the announcement said.

Innovative Industrial Properties (NYSE:IIPR)

This company’s focus on cannabis comes through the acquisition of industrial real estate assets for the growth of medical cannabis. “Concurrently with our acquisition of these properties, we enter into leases with the state-licensed growers under long-term, triple-net lease agreements,” the company said.

As part of their third quarter financial results, the company announced detailed updates for facilities it held in Maryland, New York, and Minnesota. They also revealed there was an ongoing review for $100 million worth of new potential properties.

Insys Therapeutics (NASDAQ:INSY)

Their work with cannabis relates to the development of pharmaceutical cannabinoids. Their pipeline in this area currently holds two candidates involved in a variety of trials. The most advanced includes treatments for childhood absence epilepsy and infantile spasm through a cannabidiol oral solution.

During the month of December 2017, the company provided two updates for their cannabinoids programs. First, Insys announced the start of its phase 2 clinical study for their CBD oral solution against childhood absence epilepsy. The company then announced the FDA had granted it a Fast Track designation for their Prader-Willi syndrome treatment. Insys plans to start the clinical development program for this candidate in their 2018 first quarter.

Intec Pharma (NASDAQ:NTEC)

Intec completed a phase 1 clinical trial of their Accordion Pill platform in combination with CBD and tetrahydrocannabinol (THC). “The study results showed that AP-CBD/THC had significant improvements in exposure of CBD (290 percent – 330 percent) and THC (25 percent – 50 percent) compared with Sativex,” the company explained.

In January the company announced it had obtained a Canadian patent for their Accordion Pill.

Invictus MD (OTC:IVITF)

Invictus is Canadian producer involved with a variety of ventures to increase their reach in the cannabis industry. In February the company provided shareholders with an update and a closer look at its phase 2 facility expansion.

“Both the Phase 1 and Phase 2 facilities at Acreage Pharms, located in west-central Alberta, have a total of approximately 40,000 square feet with expected 5,000 kilograms of capacity beginning in February 2018, along with a further planned 80,000 square foot Phase 3 expansion for total combined production capacity of 19,000 kilograms in 2018,” the company revealed in their announcement.

Isodiol International (OTC:ISOLF)

Isodiol is a company working in the manufacturing and development of CBD consumer products. The company received a regulatory approval for their candidate Isodiolex treating epilepsy and Parkinson’s disease, by the Brazilian Health Regulatory Agency (ANVISA).

“We have been working towards additional products for the Brazilian medical community and for the last several months, so to have our second product medically approved by ANVISA is a tremendous breakthrough for the company,” Marcos Agramont, CEO of Isodiol said of the approval.

Kush Bottles (OTC:KSHB)

Kush Bottles is a company based in California working as an ancillary operation alongside the growth of the cannabis industry itself. While holding no direct contact with the actual plant itself, Kush sells packaging supplies for dispensaries and other businesses. Their expansion since launch has allowed them to sell accessories as well as develop their own brand of products.

In one of its most recent announcements, Kush Bottles shared with investors it was picked by Future Farm Technologies (CSE:FFT; OTCQB:FFRMF) to develop them a customized “packaging and comprehensive compliance solutions.”

Lexaria Bioscience (OTCQX:LXRP)

Lexaria is a company focused on enhancing the flavor, bouquet gastrointestinal delivery of edible cannabinoid consumer products. This year the company started trading on the OTCQX Best Market.

Most recently, on January 25, the company announced a partnership with Cannfections Group, a cannabis chocolate manufacturer, in which Lexaria provided their DehydraTECH for the development of “next-generation performance in cannabis-infused chocolates and candies.”

MYM Neutraceuticals (OTC:MYMMF)

MYM Nutraceuticals is focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. Recently the company was part of a Deloitte report, “Economic Impact Assessment for the Weedon Project,” evaluating the benefits of the Wheedon Project in Quebec and Canada.

“We are in the final stages of lining up financing and making the necessary plans to break ground in Weedon to start building one of the world’s largest greenhouse facilities,” Rob Gietl, CEO of MYM said as part of the announcement.

Namaste Technologies (OTC:NXTTF)

Namaste is a company offering consumers an entirely new platform where they can access and purchase vaporizer products from official manufacturers, and if allowed by the country medical cannabis. In Canada, the company has signed deals with licensed producers (LPs) to offer their products in the NamasteMD app. Through the mobile application, patients can obtain a prescription for medical marijuana.

Sean Dollinger, president, and CEO of Namaste told INN the company plans to launch a smartwatch app that will be able to collect data from the users after consuming cannabis products.

Phivida Holdings (OTC:PHVAF)

Phivida works on a brand of CBD infused functional foods and beverages and clinical CBD products. The company updated shareholders on the production capabilities for their rollout of products in the California market. Among these products is their recently revealed Nano-CBD Iced Teas.

“Phivida’s Nano-CBD Iced Tea blends are designed to treat the GI-tract, and maximize the body’s ability to absorb orally ingested cannabinoids and phyto-nutraceuticals,” the company indicated.

Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba is a specialty pharma company working on pharmaceutically-produced transdermal cannabinoid treatments. Their pipeline of candidates holds two cannabis-related products in various trials for different diseases like Fragile X Syndrome and Tourette Syndrome.

As part of an update to shareholders on their 2018 goals, the company announced it would refocus on rare neurological and psychiatric disorders. The company was encouraged by the data from the recent ZYN002 clinical data it obtained.

“We plan to initiate a pivotal study for ZYN002 in FXS that should read out in 2019, initiate two new Phase 2 studies in refractory epilepsies, and initiate a Phase 2 program with ZYN001 in Tourette Syndrome,” Armando Anido, Zynerba’s chairman and CEO.

Source: https://investingnews.com/daily/resource-investing/agriculture-investing/cannabis-investing/american-cannabis-stocks/